Xadago launched; eyes now on pipeline assets
Following an encouraging year to date we have upgraded our forecasts for Xadago (Parkinson’s disease [PD] therapy), and key CNS pipeline assets...
232 Views
Xadago receives FDA approval in PD
Newron and its partners Zambon and US WorldMeds have announced that the FDA has approved Xadago (safinamide) for Parkinson’s disease (PD) patients...
261 Views
Marching into 2017
We anticipate that the sales and pipeline progression made by Newron in 2016 will be cemented further in 2017/18. A critical catalyst remains the...
140 Views